ARTICLE AD BOX
Mumbai: Pharmaceutical API maker Shilpa Medicare Limited has delivered a breakthrough performance for the financial year 2026, with consolidated revenues rising 18% year on year to ₹1,549 crore from ₹1,310 crore during the same period last year. This has also meant a rise in net profit to ₹232 crore (adjusted) from ₹99 crore last year, a 135% rise.
The company’s API business has seen a 16% year-on-year growth, bolstered by captive demand for its oncology and non-oncology verticals. It has also worked to add 37 new DMF filings this year. Along with this, its formulations business has delivered a 30% year on year growth, crossing the ₹200 crore revenue milestone. To diversify its energy requirements, the company is investing ₹4.44 crore to acquire 28% of New Green Power Project Private Limited, through its wholly owned subsidiaries Shilpa Biologicals and Shilpa Pharma Lifesciences Limited.
“The momentum we built since the start of FY25 is only accelerating, as we close FY26 on a strong footing while leveraging considerable progress made across all verticals. For FY26, our revenue grew by 18%, with EBITDA registering robust growth of 30% (YoY) and a healthy margin of 29%.
As we move forward, we are well-positioned to reap the benefits of continued investments in strengthening our capabilities both on R&D and manufacturing fronts, allowing us to build a differentiated portfolio across all the verticals and establish ourselves as a one-stop CDMO partner. Our novel first-in-class product NorUDCA for NAFLD continues to exceed expectations with robust offtake from partners and strengthening our Domestic FDF performance. With a significantly large addressable market ahead of us, we are building on this success by progressing regulatory filings across multiple emerging markets.
On the international FDF front, growth across geographies has been very encouraging as we position the Company for its next phase of scale-up. We are leveraging our differentiated manufacturing platform — with the expected launch of our first transdermal patch product in the EU in the coming quarters, and our first-ever transdermal patch submission to the USFDA completed during 4QFY26.
Our API business remains the backbone of our FDF growth, with most FDF products being vertically integrated — driving higher internal API utilization and contributing to improved margins. In our Biologics vertical, we have strategically monetized our development and manufacturing capabilities through high value collaborations for global markets. Building on this momentum, we are co-developing 2 NBEs and 1 NCE with global partners, establishing Shilpa as a preferred CDMO for novel product development.
Overall, our improving ROCE reflects how operational momentum is translating into greater capital efficiency. With a strong R&D pipeline and strategic partnerships fueling market share gains, we are on track for a stronger FY27,” Mr. Vishnukant Bhutada, Managing Director, Shilpa Medicare said in a press release.
The company has recommended a final dividend of ₹0.60 per equity share of face value ₹1 each for the financial year 2025-26 subject to approval from shareholders.
English (US) ·